PLIANT THERAPEUTICS, INC.·4

Jun 12, 5:00 PM ET

Huh Hoyoung 4

4 · PLIANT THERAPEUTICS, INC. · Filed Jun 12, 2026

Research Summary

AI-generated summary of this filing

Updated

Pliant Therapeutics (PLRX) Director Huh Hoyoung Receives 70,000-Share Grant

What Happened

  • Director Huh Hoyoung was granted a 70,000-share derivative award (listed as a grant, Form 4 code "A") on 2026-06-11. The filing reports an acquisition price of $0.00 and a reported total value of $0 on the Form 4. The footnote to the filing indicates these are options that vest and become exercisable on a schedule described below.

Key Details

  • Transaction date: 2026-06-11; filing date: 2026-06-12 (appears timely).
  • Instrument: derivative grant (option) for 70,000 shares; reported acquisition price $0.00.
  • Vesting schedule (per footnote): 25% vest and become exercisable on each of Oct 1, 2026; Jan 1, 2027; and Apr 1, 2027; the remaining 25% vests on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders — all subject to continued service as a director.
  • Shares owned after transaction: not disclosed in the provided filing.
  • Filing code: A = award/grant. No 10b5-1, tax-withholding, or sale noted in this filing.

Context

  • This is a compensation-related option grant to a director rather than an open-market purchase or sale. The award vests over time and does not reflect an immediate cash outflow or sale of shares. Such grants are common for board compensation; they establish future potential ownership if vesting and exercisability conditions are met.

Insider Transaction Report

Form 4
Period: 2026-06-11
Huh Hoyoung
Director
Transactions
  • Award

    Stock Option (Right to Buy)

    [F1]
    2026-06-11+70,00070,000 total
    Exercise: $1.14Exp: 2036-06-11Common Stock (70,000 underlying)
Footnotes (1)
  • [F1]25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.
Signature
/s/ Jennifer Woo, attorney-in-fact|2026-06-12

Documents

1 file
  • 4
    wk-form4_1781298056.xmlPrimary

    FORM 4